Robert W. Baird Analysts Give Davita (DVA) a $97.00 Price Target

Davita (NYSE:DVA) has been assigned a $97.00 price objective by research analysts at Robert W. Baird in a research report issued to clients and investors on Tuesday. The brokerage currently has a “buy” rating on the stock. Robert W. Baird’s price target points to a potential upside of 32.57% from the company’s current price.

A number of other brokerages have also recently issued reports on DVA. Zacks Investment Research cut Davita from a “buy” rating to a “hold” rating in a research note on Tuesday. Bank of America restated a “buy” rating and issued a $92.00 price objective (up from $85.00) on shares of Davita in a research note on Thursday, January 11th. TheStreet upgraded Davita from a “c” rating to a “b-” rating in a research note on Thursday, January 4th. SunTrust Banks set a $75.00 price objective on Davita and gave the company a “hold” rating in a research note on Thursday, December 21st. Finally, Citigroup upgraded Davita from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $67.71 to $82.00 in a research note on Monday, December 11th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $78.80.

Shares of Davita (NYSE:DVA) traded down $0.37 during trading hours on Tuesday, hitting $73.17. 1,281,814 shares of the company were exchanged, compared to its average volume of 1,399,521. The company has a quick ratio of 1.35, a current ratio of 1.40 and a debt-to-equity ratio of 1.79. The stock has a market cap of $13,456.05, a P/E ratio of 28.20 and a beta of 0.99. Davita has a 52 week low of $52.51 and a 52 week high of $80.71.

Davita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $0.92 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.02). The company had revenue of $2.78 billion during the quarter, compared to analysts’ expectations of $3.90 billion. Davita had a return on equity of 13.31% and a net margin of 3.40%. During the same period last year, the firm posted $0.98 earnings per share. analysts predict that Davita will post 3.44 EPS for the current year.

In other Davita news, VP Leanne M. Zumwalt sold 949 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $68.19, for a total value of $64,712.31. Following the completion of the sale, the vice president now owns 12,423 shares of the company’s stock, valued at $847,124.37. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Charles Berg sold 7,048 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $69.24, for a total value of $488,003.52. Following the completion of the sale, the insider now directly owns 5,359 shares of the company’s stock, valued at approximately $371,057.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 121,509 shares of company stock worth $8,310,388. Company insiders own 2.00% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Coastline Trust Co boosted its stake in Davita by 6.3% in the fourth quarter. Coastline Trust Co now owns 16,120 shares of the company’s stock worth $1,165,000 after buying an additional 950 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its stake in Davita by 3.5% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 29,076 shares of the company’s stock worth $2,101,000 after buying an additional 974 shares in the last quarter. Creative Planning boosted its stake in Davita by 8.6% in the fourth quarter. Creative Planning now owns 13,137 shares of the company’s stock worth $949,000 after buying an additional 1,044 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in Davita by 7.0% in the fourth quarter. Crossmark Global Holdings Inc. now owns 25,163 shares of the company’s stock worth $1,818,000 after buying an additional 1,650 shares in the last quarter. Finally, Amalgamated Bank boosted its stake in Davita by 9.7% in the fourth quarter. Amalgamated Bank now owns 19,246 shares of the company’s stock worth $1,391,000 after buying an additional 1,698 shares in the last quarter. 84.45% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/robert-w-baird-analysts-give-davita-dva-a-97-00-price-target.html.

Davita Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply